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The revelation of the human genome has enabled scientists to assess the disposition
and response of an organism to an environmental stimulus; transcriptomics,
proteomics, and metabonomics can each generate such holistic views.
Nutrigenomic techniques help researchers elucidate individual responses to
nutritional interventions holistically and help with the design of personalized diets
adapted to individual needs. Human genetics has revealed insights into health and
disease susceptibility and can help diﬀerentiate responders from nonresponders in
dietary interventions, but the predictive power of single-nucleotide polymorphisms
in disease susceptibility genes has so far been limited in terms of helping to foresee a
health trajectory. Epigenetics encompasses alterations of genetic material that do
not aﬀect the DNA nucleotide sequence; these include DNA methylation patterns,
chromatin structure, histone codes, and non-coding small RNAs. DNAmethylation is
modiﬁed particularly around the time of birth; therefore, early-life nutrition may
aﬀect health outcomes later in life.
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INTRODUCTION
Catalyzed by the revelation of the human genome,1,2
genomics can now assess the disposition, response, or
expression of a living system (cell, organ, and entire
organism) to an environmental (e.g., nutritional) stimu-
lus or challenge; transcriptomics, proteomics, and meta-
bonomics can generate such holistic views of biological
conditions at the levels of the gene transcript, protein, and
metabolite.3 Although genetics provides a blueprint (i.e.,
what may happen), the transcripts provide an action plan
(i.e., what appears to happen), the proteins are what make
it happen, and the metabolites can tell a story (i.e., what
has happened).4
Broadly deﬁned, human genetics is the study of the
human genome sequence and its interindividual varia-
tions; it can reveal insights into health prospects and
disease susceptibility5 and can diﬀerentiate responders
from nonresponders in dietary interventions.6 Although
the latter genetics-based cohort stratiﬁcation has been
shown to be possible and powerful in certain cases, the
predictive power of single-nucleotide polymorphisms
(SNPs), or combinations of them, found in so-called
disease susceptibility genes and revealed as risk loci, has
been relatively limited when it comes to foreseeing a
health trajectory or disease onset.7,8 These SNPs could,
so far, only explain a small degree of the phenotypic
variability in question.9 Apparently, the genomic com-
pensation around these SNPs is important, so the same
set of SNPs may matter for one (sub)population but not
for another. This might be one of the reasons why rep-
lication of risk loci in diﬀerent populations is still
diﬃcult.10 These ﬁndings contrast somewhat with the
blossoming of genetic counseling companies that
provide consumers with risk assessment and life-style
recommendations based on their individual genetic
proﬁle (e.g., their particular set of SNPs in disease-
related genes).11
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Epigenetics is an even newer ﬁeld of genetic and
genomic sciences. It literally means “above genetics” and
alludes to alterations of genetic material that do not aﬀect
the DNA sequence itself, i.e.,DNAmethylation patterns,12
chromatin structure,13 and histone codes,14 as well as non-
coding small RNAs.15 DNA methylation can be exerted at
susceptible life phases (especially around birth) and last
for a life phase, the entire lifespan, or even several genera-
tions. It seems to provide a major format for long-term
metabolic imprinting of an organism; thus, early-life
nutrition may aﬀect later-life health outcomes.16 Like
DNA methylation patterns, DNA packaging proteins
such as histones and the entire chromatin structure also
aﬀect gene expression by rendering only certain parts of
the DNA material spatially accessible for transcription.17
Small RNAs can bind to complementary transcripts and
prevent them from being processed further, thereby alter-
ing protein expression.15 Overall, epigenetic modiﬁca-
tions can exert a long-term eﬀect on gene expression.
This article focuses on the deployment of genetics
(with a strong focus on G proteins) and epigenetics to
assess individual disposition for response to (nutritional)
intervention. It also alludes to the scientiﬁc interfaces
among genes, nutrition, and the brain. Knowledge about
the binary interfaces of these disciplines has been accu-
mulated, but little is known about the intersection of all
three scientiﬁc domains (e.g., about how genes aﬀect
human brain development and decline or how humans
diﬀer in their amenability to nutritional intervention
aimed at promoting brain development and preventing
neuronal decline and loss of cognitive function).
GENETICS
Genetics and nutrition
Nutrigenetics assesses an individual’s genetic predisposi-
tion to diet. SNPs are point mutations in genes and
account for the most common and important interindi-
vidual genetic diﬀerences at the sequence level known to
date.18 These SNPs occur in exons and introns (in coding
and noncoding DNA regions), and many have important
functional consequences.19
G proteins
As one of the few established examples for stratiﬁcation of
cohorts in nutritional intervention studies based on
genetic variants in a given class of proteins, the case of G
protein polymorphisms is discussed here.Genetic predis-
positions with regard to cognitive performance and
decline, as well as to possible nutritional interventions,
are discussed in the section titled “Genes, nutrition, and
the brain.”
G proteins are expressed in all cells of the human
body; their main role is to translate signals from the cell
surface into a cellular response.20 G proteins are hetero-
trimers and are composed of a, b, and g subunits. The
family of G proteins comprises 18 a subunits, 5 b sub-
units, and 12 g subunits encoded by diﬀerent genes,21
which enables the formation of highly variable G protein
heterotrimers. The a-, b-, and g-subunit composition of
G proteins determines their receptor and eﬀector speci-
ﬁcity.22 Given the pivotal role of G proteins in virtually all
intracellular signal transduction processes, it is assumed
that mutations altering the expression or structure of
these proteins causes or contributes to health disorders.6
Metabolically relevant SNPs in G proteins have been
characterized.6,23–29 In Caucasians, the genotype distribu-
tion of the C825T polymorphism in the G-protein b3
(GNB3) subunit gene is 10% TT, 45% TC, and 45% CC,
with an average frequency of the T allele near 30%. Some
ethnicities have 70–80% frequencies of the C825T allele,
and in these populations, the CC genotype is rare.30 These
variations in the C825T allele have important metabolic
eﬀects, as discussed below.
Weight management. G-protein gene variants have been
shown to be directly implicated in weight regulation.23–25
The C825T polymorphism of the GNB3 subunit gene
allows the prediction of whether weight reduction under
sibutramine therapy will be successful. Sibutramine is a
centrally acting noradrenaline and serotonin reuptake
inhibitor; it enhances satiety and is used extensively to
support weight loss. In a reduced-calorie weight-loss
intervention study, the CC-genotype obese subjects ben-
eﬁted from sibutramine, whereas the CT-genotype indi-
viduals did not.25
A similar observation has been made for the GNAS
gene, which encodes the G protein Gas ("stimulatory" G
protein) mediating the increase in cyclic adenosine
monophosphate in many cell types following hormonal
stimulation. The GNAS G(-1211)A genotype also inﬂu-
ences the subject’s response to sibutramine-induced
weight-loss intervention. Whereas individuals with the
GG genotype can lose weight without the drug and are
even at risk for exaggerated heart rate changes without
beneﬁting from the drug, carriers of the A allele beneﬁt
from adjunct drug therapy. Several further SNPs occur in
the GNAS gene, which together form a relevant
haplotype.
The GNA11 G(-659)C genotype in the G protein
Ga11 also has a strong inﬂuence on the sibutramine inter-
vention; individuals with the CC genotype lose up to 20%
of their original body weight, those with the GC genotype
lose 10%, and those with the GG genotype lose barely
more than 8% under drug treatment. As for GNAS
G(-1211)A, individuals with the GG genotype are at risk
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for exaggerated changes in heart rate.23 Taken together,
these results suggest that G-protein–directed genotyping
could make sibutramine therapy safe and eﬃcient, as well
as making a nutritional intervention generally more
powerful.
Many women struggle with post-pregnancy weight
retention. Studies of young female subjects of diﬀerent
ethnic backgrounds suggest that GNB3 825T carriers
have a greater risk of developing obesity and post-
pregnancy weight retention. The 825T allele of the
G-protein b3 gene is associated with higher body mass
index (BMI) across diﬀerent ethnicities. Primiparous
homozygous carriers of the GNB3 825T allele are at high
risk of obesity and post-pregnancy weight retention.24
These investigations have been conﬁrmed in white sub-
jects with and without hypertension.
Hypertension and metabolic syndrome. The majority of
G-protein studies in Caucasians reveal a positive associa-
tion between 825T allele carrier status in the GNB3
subunit gene and risk of hypertension. This has been
demonstrated in particular for large populations geno-
typed from a German and Belgian study.6 There is evi-
dence that 825T allele frequency is greater in patients
with hypertension and typical features of the metabolic
syndrome6; young, lean, normotensive male 825T allele
carriers already display features of the metabolic syn-
drome, such as high total cholesterol and uric acid con-
centration but not yet insulin resistance. Similar
metabolic deviations were found in older European and
Japanese subjects. In older subjects with hypertension and
the TT or TC genotype of GNB3, insulin resistance
appears to be more common than in individuals with the
CC genotype. Taken together, the cited studies raise
the question of whether hypertension associated with the
C825T polymorphism may be just one feature of the
metabolic syndrome. The 825T association with risk of
type 2 diabetes mellitus remains to be proved.6
Atherosclerosis. A few studies, most of them performed
in Caucasian populations, examined the association
between the C825T allele in the G-protein b3 subunit
gene and atherosclerosis, pre-atherosclerotic phenotypes,
stroke, and myocardial infarction. Young, white, male
825T allele carriers have greater cardiac stroke volume,
greater arterial stiﬀness, and greater prevalence of radial
artery hypertrophy. The last association is independent of
age, blood pressure, and BMI.6
Digestive health and comfort. Irritable bowel syndrome
and functional dyspepsia are well-recognized functional
gastrointestinal disorders. These conditions are highly
prevalent and often overlap. A clear association was
found between the CC genotype of the GNB3 subunit
gene and functional dyspepsia; homozygous G-protein
b3 825C carriers are associated with unexplained, pre-
dominantly upper abdominal symptoms, although no
ﬁrm conclusion could be drawn with regard to associa-
tions with irritable bowel syndrome.26
EPIGENETICS
What is epigenetics?
As mentioned above, the word “epigenetics” means
“above genetics” and generally refers to mechanisms that
control gene expression without changing the DNA
sequence. Epigenetic changes encompass molecular
modiﬁcations to DNA and chromatin.12,13 The most
extensively investigated modiﬁcations are DNA methyla-
tion and changes to chromatin packaging of DNA by
post-translational histone modiﬁcations.12,13 Other epige-
netic mechanisms include regulation by noncoding
RNAs, such as microRNAs, and mechanisms that control
the higher-level organization of chromatin within the
nucleus, which also aﬀects gene expression.31 Two of the
most comprehensively studied epigenetically regulated
phenomena in mammals are X-chromosome inactiva-
tion32 and genomic imprinting, a genetic mechanism that
controls gene expression in a parent of origin–speciﬁc
manner.16,33 Epigenetic regulation is furthermore
involved in tissue-speciﬁc gene expression and
silencing.34
Disorders involving dysfunction of imprinted genes
are likely to have an epigenetic component. Individuals
have two copies, or alleles, of most genes.One is inherited
from the mother and one from the father. When both
copies of a gene are active, the system exhibits redun-
dancy and hence is less susceptible to dysfunction, but
with imprinted genes, one copy is turned oﬀ epigeneti-
cally. These imprinted genes are susceptibility loci for
disease because a single genetic event can alter their
normal function.35 Epigenetic events can also cause or
contribute to diseases if imprinted genes are not com-
pletely turned oﬀ.
Epigenetic modiﬁcations alter gene expression but
not gene sequence. Therefore, characterizing the expres-
sion proﬁles of epigenetically controlled genes should
reveal epigenetic biomarkers for disease, exposure, inter-
vention, and eﬃcacy. In turn, this should enable early
diagnosis of individuals with a propensity for adult-onset
disease and could lead to novel therapeutic approaches
that could prevent and treat diseases before symptoms
develop. This is in contrast with current human disease
management, which mainly treats diseases after onset. In
particular, modern nutrition focuses on disease preven-
tion and health maintenance, and epigenetics may
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provide the means to understand and achieve these goals.
Ultimately, comprehensive knowledge of the human
epigenome is required, because the epigenome is not only
tissue and stage-of-life dependent, it also varies markedly
between individuals and species.
Epigenetics provides a biological format of long-
term eﬀects of environmental experiences, metabolic
programming, and adaptive development of an organ-
ism.31 Epigenetic changes occur most commonly during
gestation, neonatal development, puberty, and old age.
During early embryogenesis, the mammalian genome is
“cleansed” of most epigenetic marks, which are progres-
sively re-established during embryonic development.36
The epigenome is therefore most vulnerable to environ-
mentally induced alterations during embryogenesis,
when DNA synthesis is rapid and the DNA methylation
pattern and chromatin structure required for normal
development is established. Once established, these epi-
genetic alterations are passed on to the daughter cells
during somatic cell division. Epigenetic marks that are
not completely erased during gametogenesis or are not
well re-established during embryonic development can
aﬀect health not only in the present, but also in future
generations.35 In addition, epigenetic marks may be trans-
mitted across generations, either directly, by persisting
through meiosis, or indirectly, through replication in the
next generation of the conditions in which the epigenetic
change occurred.36 Compelling evidence supports both
the developmental origins of health and disease and the
underlying epigenetic mechanisms.36
There is little doubt that environmentally (e.g., nutri-
tionally) induced changes may signiﬁcantly aﬀect the
ontology of individual organisms. Epigenetic research
involving monozygotic twins has provided evidence for
this hypothesis.37 Such studies typically provide correla-
tions between phenotypic diﬀerences and diﬀerences in
DNA-methylation patterns. Little is known about genes
that are particularly prone to undergo environmentally
inﬂuenced epigenetic changes and about the role of such
changes in the generation of speciﬁc phenotypes. Conse-
quently, analysis of environmentally or nutritionally
induced epigenetic changes should primarily focus on the
few“metastable” epialleles that have been characterized to
date,31 on imprinted genes, and on genes known to be
associated with a particular phenotype, such as obesity.
Regarding the latter gene type, experiments should con-
centrate on the genes carrying CpG islands, because these
are frequently methylated.
Environmental inﬂuences can alter gene expression
and change phenotype, in part by modifying the epige-
nome. If these environmentally induced epigenetic modi-
ﬁcations occur at crucial stages of life, they can potentially
change behavior, disease susceptibility, and survival.
Today’s mechanistic evidence of environmental epige-
netic imprinting or programming, by nutritional or other
means, mainly derives from animal models, but human
epidemiological studies also point increasingly toward
associations between environmental eﬀects – especially
prenatal and early postnatal – and long-term epigenetic
modiﬁcations manifesting in health and disease pheno-
types.38,39 Results of animal and human studies support
the hypothesis that there is a fetal basis or developmental
origin of adult-onset disease; evolution of developmental
plasticity,which enables an organism to adapt to environ-
mental signals during early life, can also increase the risk
of chronic diseases when there is a mismatch between the
early perceived environment and the one encountered in
adulthood. Developmental plasticity manifests when
environmental exposure produces a broad range of adult
phenotypes from a single genotype by epigenetically
altering gene expression.40,41
Early nutrition, late-life consequences,
and epigenetics
The fetal environment can inﬂuence an individual’s like-
lihood of developing chronic disorders during adulthood.
Early evidence of this appeared in research showing
higher rates of cardiovascular disease in historical cohorts
that had experienced high infant mortality.36 Further
studies revealed an inverse relationship between birth
weight and the development of hypertension, cardiovas-
cular morbidity, insulin resistance, type 2 diabetes melli-
tus, hyperlipidemia, and obesity.36 It was therefore
hypothesized that fetal metabolic programming under
nutritionally adverse circumstances (i.e., those under
which fetal growth is restricted in order to ensure brain
development) may result in greater risk of chronic disor-
ders later in life,42 although other data (e.g., from survi-
vors of the Dutch “hunger winter” of 1944/1945) indicate
that individuals exposed to adverse conditions in utero
may subsequently exhibit adverse eﬀects even if they do
not have a low birth weight.38 This observation is consis-
tent with the complex relationship between birth weight
and risk of cardiovascular disease43 and with the observa-
tion that metabolic dysfunction correlates more strongly
with neonatal adiposity and maternal nutrition than with
birth weight.39,44
Other studies have focused on the role of excess
nutrition during pregnancy and rapid weight gain in
infants,40 the risk of which is greater after impaired fetal
growth.Also, children who are exposed to hyperglycemia
in utero or whose mothers are obese are at greater risk of
developing metabolic disorders, especially type 2 diabetes
mellitus.41 Most studies performed so far, however, have
focused on the pathways through which undernutrition
during development translates into subsequent metabolic
disease, despite the fact that fetal nutrition depends not
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on maternal food intake but on maternal metabolism,
cardiovascular function, and, particularly, placental
function.36
Developing organisms seem to be particularly sus-
ceptible to epigenetic changes. The periconceptional
period is particularly important, as shown by the sensi-
tivity to suboptimal nutrition that occurs during this
developmental stage45,46 in which widespread reprogram-
ming of the epigenome occurs.47 Nutritional constraints
later in pregnancy38,48 and/or postnatal overnutrition that
leads to rapid growth,40,48 as well as maternal–fetal over-
nutrition,49 can also cause metabolic dysfunction later in
life. For each of these scenarios, relevant epigenetic
changes have been reported.50–52
The importance of the periconceptional period,
during which suboptimal nutrition can have long-lasting
eﬀects without causing any change in birth weight,38,46
underscores the importance of healthy nutrition during
the prepregnancy period. During this time, nutrition
may frequently be unbalanced, even in women in high-
income countries.53 The related ﬁnding that the balance
of micronutrients involved in one-carbon metabolism
during pregnancy aﬀects the subsequent metabolic
health of the oﬀspring54 has implications for the design
of nutritional supplementation programs. Research in
animal models has demonstrated that nutritional
interventions (such as folate supplementation) or endo-
crinological interventions (such as neonatal leptin
administration) can prevent55 or reverse52,56 the adverse
eﬀects of impaired early-life nutrition and the associated
epigenetic changes.
Maternal overnutrition may contribute to trans-
generational ampliﬁcation of obesity in humans.57 In the
Agouti mouse model, dietary supplementation with sub-
strates and cofactors of DNA methylation abrogate such
female-line transmission of obesity.58 Also, early treat-
ment with a histone deacetylase inhibitor, a drug class for
clinical oncological trials, can reverse the phenotypic and
epigenetic consequences of intrauterine growth retarda-
tion for pancreatic development and adult-onset diabetes
mellitus.59 Oﬀspring of rats given a low-protein diet
during pregnancy have a diﬀerent hepatic gene expres-
sion, gene promoter methylation, and histone acetylation
of metabolically relevant receptors: the glucocorticoid
receptor and the peroxisome proliferator-activated recep-
tor a. Later in life, the oﬀspring develop abnormalities of
metabolic control and cardiovascular function. Concur-
rently supplementing the diet of the pregnant dam with
folate, which promotes methyl group provision, prevents
these eﬀects.55 Studies in pregnant rodents subject to a
variety of dietary challenges or to exposure to glucocor-
ticoids show a relatively consistent outcome for the oﬀ-
spring, i.e., abnormalities of insulin secretion and
sensitivity, sarcopenia, appetite disturbance, obesity, and
endothelial dysfunction.60 These features are particularly
apparent when the animals are placed on a high-fat diet
after weaning.48
Primary candidates for genes holding epigenetic
memories of early-life experiences are those that are
directly associated with energy acquisition, storage, and
use. Leptin is thought to be one of the best gene candi-
dates involved in the development of obesity, because it
encodes a hormone that regulates energy intake and
expenditure.61 Epigenetic variants of leptin could possibly
explain low plasma concentrations of this fat hormone.
The promoter region of leptin is methylated in somatic
tissues of humans and mice and displays epigenetic
variation.62–64 It is speculated that leptin is sensitive to
environmental cues and can acquire a thrifty epigeno-
type. Other promising candidates are genes listed in the
human obesity gene map,65 imprinted genes, and genes
close to or disrupted by transposable elements.
Genes, nutrition, and the brain
A great deal of research has focused on the respective
binary research interfaces of genomics, cognitive science,
and nutrition research, but little is known about the inter-
section of all three disciplines. For example, how does
nutrition aﬀect the brain at the whole genome level? And
how does an individual’s genetic make-up determine
their nutritional response with consequences for cogni-
tive performance and for predisposition toward cognitive
decline and disease?
A substantial body of knowledge has already been
gathered regarding the interface between nutrition and
genes; the ﬁelds of nutrigenomics (e.g., how the body
responds to diet at the genomic scale)66 and nutrigenet-
ics67 (e.g., how individuals are predisposed to respond to
food in a certain way and not in another) are rapidly
expanding this knowledge.68 The nutrigenetic success
story of G-protein polymorphisms was discussed in the
preceding section.
Competence is also improving in the interface
between nutrition and the brain; that is, how diet aﬀects
neurodevelopment,69 neurodecline,70 and cognitive per-
formance.71 However, such studies are typically epide-
miological, observational, or associative.
Furthermore, knowledge is accumulating regarding
the interface of the brain and the genes (e.g., how indi-
viduals are predisposed to the development of cognitive
decline72,73 and disease74 and to respond to nutritional
intervention aimed at improving neurodevelopment and
cognition as well as preventing neurodecline75). In recent
pioneering studies, initial understanding of how epige-
netic and genetic mechanisms may inﬂuence cognitive
function76 and neuronal disease has been gained.77 Kalu-
eﬀ78 reviewed the neurobiology of memory and anxiety
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with the ultimate goal of making the leap from genes to
behavior; he summarized experimental data from neuro-
genetics, neurochemistry, behavioral pharmacology, and
clinical ﬁndings reﬂecting mechanisms of the interplay
between memory and anxiety, including brain neuro-
chemistry and circuitry, pharmacology, neuroplasticity,
genetics, and interactions between genes and environ-
ment.78 Burmeister et al.79 recently updated the science
community on progress and controversy in psychiatric
genetics; although several psychiatric diseases such as
bipolar disorder, schizophrenia, and autism are highly
heritable, identifying their genetic basis and replicating
the ﬁndings are challenging. Nevertheless, the incorpora-
tion of intermediate traits (endophenotypes) and envi-
ronmental factors into genetic analyses and the
identiﬁcation of rare inherited variants and novel struc-
tural mutations have advanced the ﬁeld. The same is
expected from larger sample sizes and meta-analyses of
such studies and from paying more attention to unique
families and rare variants.80
The Papassotiropoulos group has shed more light on
the genetic basis of cognitive performance and decline; as
a methodological recommendation, they suggest identi-
fying the genetic basis for complex disorders using
pooling-based genome-wide SNP association studies as a
low-cost alternative to individually genotyping thousands
of samples on high-density SNP microarrays.81 They also
reviewed the application of genetics, transcriptomics, and
proteomics to Alzheimer’s disease (AD),81 discussing, for
example, rare mutations of APP and presenilin 1/2 and
their importance for amyloid metabolism81 and apolipo-
protein E (APOE) as an important susceptibility gene for
late-onset AD.82 The same group, together with others,
has also published a number of research articles on asso-
ciations between genes and performance, with a focus on
memory; except for a genome survey of human short-
term memory,83 memory performance was concretely
associated with genetic variability in a gene locus encod-
ing the brain protein KIBRA84; APOE, the major genetic
AD risk factor85 (with the APOE e4 allele associated with
better episodic memory than the APOE e2 and e3 alleles
in young, healthy persons); a gene cluster encoding pro-
teins of a signalling cascade encompassing the N-methyl-
D-aspartic acid and metabotropic glutamate receptors,
adenylyl cyclase, Ca 2+/calmodulin-dependent protein
kinase II, protein kinase (pK) A, and pKC86; and the
calmodulin-binding transcription activator 1 gene87
(which inﬂuences episodic memory). In an extension of
the genetic determination of memory, de Quervain et al.88
assessed emotional memory and identiﬁed an association
with a deletion variant of the a2b-adrenoceptor, which is
related to diﬀerential amygdala activation during encod-
ing of emotional memories.89 Payton et al.90 assessed the
inﬂuence of serotonin transporter gene polymorphisms
on cognitive decline and cognitive abilities in older adults
without dementia, focusing on two functional SNPs
within the SLC6A4 and VNTR2 genes. They found sub-
jects homozygous for the VNTR2 12 allele to decline
more rapidly on all cognitive tests, with signiﬁcance
reached for tests of ﬂuid intelligence, semantic memory,
and general cognitive ability. VNTR2 is only the second
gene reported to regulate the rate of cognitive decline in
individuals without dementia, and it may become a target
for the treatment of cognitive impairment in older
adults.90
Although these pioneering studies point toward
genetic susceptibility loci, replication of such ﬁndings in
genome-wide association studies (GWAS) has been chal-
lenging, as with most complex disorders and phenotypes;
Need et al.91 performed a GWAS of 11 cognitive pheno-
types from the Cambridge Neuropsychological Test
Automated Battery. They showed these measures to be
heritable by comparing the correlation in 100 monozy-
gotic and 100 dizygotic twin pairs; the full battery was
tested in approximately 750 subjects, and a further 500
individuals were investigated for spatial and verbal rec-
ognition memory to search for smaller genetic eﬀects.
Unfortunately, the authors were not able to establish any
signiﬁcant genome-wide associations with SNPs or copy
number variants, nor could they replicate any polymor-
phism previously associated with cognition. The group
also investigated – as a separate set – SNPs in genomic
loci that had been shown to harbor rare variants associ-
ated with neuropsychiatric disorders. Only NRXN1
showed evidence of signiﬁcant association with cogni-
tion. Need et al.91 concluded that common genetic varia-
tion has little inﬂuence on cognition in healthy subjects
and that cognitive measures do not represent a more-
tractable genetic trait than clinical endpoints.
In summary, we are learning how gene variants may
inﬂuence cognitive performance on the one hand and
the outcome of nutritional interventions on the other
hand. In contrast, the intersection of genomics, cognitive
science, and nutrition research, that is, how nutrition
aﬀects the brain genome-wide and how (epi)genetics
may determine an individual’s nutritional response with
consequences for cognitive performance and decline,
remains largely uncharted terrain. This is especially true
for human studies, and one reason is the diﬃcult sam-
pling; genome-wide analyses of mechanisms of neuronal
decline in the brain are limited to animal studies or to
postmortem brain biopsies of aﬀected subjects. In the
search for early biomarkers, cerebrospinal ﬂuid (the
liquid surrounding the brain) may oﬀer an alternative,92
and cerebrospinal ﬂuid studies have identiﬁed candidate
protein biomarkers for brain diseases.93 GWAS have
revealed (candidate) genetic risk loci for diseases includ-
ing AD and Parkinson’s disease.74 To our knowledge
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(epi)genetic predisposition to cognition-promoting
nutritional interventions has not been investigated.
CONCLUSION
Research in the ﬁeld of genetics has been performed to
date in two formats: hypothesis-driven candidate gene
approaches and GWAS. The ﬁrst category of studies con-
tains examples of how genetic predisposition, for
example, in the form of SNPs (which are the most promi-
nent source of interindividual genetic variability) or copy
number polymorphisms, determines or strongly inﬂu-
ences the response to a given environmental (e.g., nutri-
tional) stimulus.
GWAS have identiﬁed a number of (candidate) risk
loci for the development or (early) onset of certain dis-
eases, including common and complex ones. However,
the power of these risk loci to predict health trajectories
has, so far, been small, even if several loci have meanwhile
been replicated and taken together in a combined score.
In contrast, combining these genetic scores with environ-
mental scores94 appears to be a more powerful tool for
predicting health outcomes and disease risk, and eventu-
ally feeds into lifestyle advice. Hence, it may become pos-
sible in the not-too-distant future to routinely genetically
stratify cohorts in clinical (nutritional or pharmaceutical)
intervention studies, discern responders from nonre-
sponders, thereby improving study readout, and to
combine genetic scores with lifestyle scores to obtain an
overall health prospect and disease risk assessment.
Epigenetics may provide mechanisms by which
metabolic programming can be understood and even
inﬂuenced. Together with genetics and genomics, it forms
a set of scientiﬁc building blocks for further developing
evidence-based and mechanism-rooted personalized
nutrition and treatment. Epigenetic changes are inter-
preted as chemical switches that can turn on and oﬀ the
expression of genes in response to environmental cues.
Defective genes are damaged for life; however, there is
emerging evidence from animal models that genes can be
demethylated or remethylated, which may open the
opportunity for reprogramming, possibly using nutri-
tional means. Epigenetic changes occur most commonly
during gestation, neonatal development, puberty, and old
age. The epigenome is most vulnerable to environmen-
tally induced alterations during embryogenesis. The
perinatal period appears to be especially prone to envi-
ronmental eﬀects that have long-term consequences for
health outcomes and disease risk. Some epigenetic
changes can increase disease risk if they lead to deregu-
lation of genes or if there is a mismatch between the
environment that is present during development and
the environment encountered in adulthood. Most of the
current evidence for epigenetic programming stems from
cancer research and derives from animal models.
Although discussions have taken place regarding whether
or not trans-generational inheritance of environmentally
induced epigenetic changes is of signiﬁcance in
mammals, there is little doubt that such environmentally
(nutritionally) induced changes may signiﬁcantly aﬀect
the ontology of individual organisms.
In our opinion, a holistic approach of genomics
(including transcriptomics, proteomics, and metabolom-
ics), genetics, and epigenetics is required to understand
human variability and to develop biomarkers for
response and eﬃcacy, individual disposition, and pro-
gramming of an organism, respectively. This concept
applies, in our view, to nutrition just as much as it does to
pharmaceutical research.
One of the reasons the understanding of environ-
mental modeling of a genome is only beginning may be
that the aforementioned integration of genomics (expres-
sion), genetics (predisposition), and epigenetics (pro-
gramming or imprinting) is just emerging and that the
tools for genome-wide analyses are still maturing. In the
ﬁelds of infant nutrition, diabetes, obesity, and the meta-
bolic syndrome, the term “metabolic programming” has
been coined to give a name to the observation that envi-
ronmental experiences early in life may be “genomically”
remembered and give rise to health outcomes manifest-
ing later in life. Epigenetics emerges as an important
mechanism underlying this phenomenon.
The phenomenon of childhood exposure resulting in
adult behavior is not new; a child who has already
watched many science ﬁction videos at an early age may
be diﬃcult to convince to read a book or to explore nature
later on. This basic educational experience may be called
an aspect of “cognitive programming.” With the mecha-
nisms responsible for this remaining largely elusive, and
with integrated genomics and (epi)genetics bearing the
potential to shed more light on it, it is the study design
and the diﬃcult sampling that render such investigations
in humans extremely challenging. The cognitive sciences
continue to thrive towards the ultimate goal of under-
standing how the brain functions. However, while
humans are developing a systems-level understanding of
biological entities less complex than humans themselves,
they are and will probably remain far away from such
systems-level understanding of their own species.
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